Evaluation of safety and efficiency of Narlaprevir in patients with chronic VHC (genotype 1) who were not treated with pegylated interferon and Ribavirin earlier or whose earlier treatment with those drugs was inefficient

Trial Profile

Evaluation of safety and efficiency of Narlaprevir in patients with chronic VHC (genotype 1) who were not treated with pegylated interferon and Ribavirin earlier or whose earlier treatment with those drugs was inefficient

Completed
Phase of Trial: Phase III

Latest Information Update: 13 Apr 2018

At a glance

  • Drugs Narlaprevir (Primary)
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Acronyms PIONEER
  • Most Recent Events

    • 13 Apr 2018 New trial record
    • 06 Jun 2016 Status changed to completed, according to a R-Pharm media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top